Loading institutional data...
Loading institutional data...
Held by 392 of 5,944 reporting institutions (96th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $111.34 today, the market must believe free cash flow compounds 1.4%/yr for a decade (off $593M normalized FCF).
The market's 1.4% is more conservative than its 9-yr track record.
2-stage DCF · 0.05B shares · net debt $2.0B
mean 15.1% · volatility σ 45% · implied rate exceeded in 4/9 yrs
Central path = implied 1.4%/yr growth; shaded band = ±1σ (45%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.20B 100.0% | $3.15B 100.0% | $3.24B 100.0% | $4.03B 100.0% | $3.25B 100.0% | $2.51B 100.0% | $2.96B 100.0% | $2.72B 100.0% | $2.34B 100.0% | $2.27B 100.0% |
| Cost of Revenue | $1.95B 60.9% | $1.90B 60.3% | $1.96B 60.4% | $2.59B 64.1% | $2.06B 63.2% | $1.63B 64.9% | $1.86B 62.7% | $1.72B 63.1% | $1.42B 60.9% | $1.37B 60.3% |
| Gross Profit | $1.25B 39.1% | $1.25B 39.7% | $1.28B 39.6% | $1.45B 35.9% | $1.19B 36.8% | $882.0M 35.1% | $1.10B 37.3% | $1.00B 36.9% | $912.7M 39.1% | $901.2M 39.7% |
| Research & Development | $58.8M 1.8% | $50.8M 1.6% | $47.1M 1.5% | $48.9M 1.2% | $41.8M 1.3% | $35.3M 1.4% | $41.2M 1.4% | $35.3M 1.3% | $29.1M 1.2% | $26.3M 1.2% |
| Selling, General & Admin | $663.2M 20.7% | $590.1M 18.7% | $624.9M 19.3% | $797.2M 19.8% | $668.0M 20.5% | $531.9M 21.2% | $593.8M 20.1% | $538.8M 19.8% | $468.2M 20.0% | $471.6M 20.8% |
| Operating Income | $574.9M 18.0% | $644.1M 20.4% | $652.4M 20.1% | $639.6M 15.9% | $630.0M 19.4% | $324.4M 12.9% | $514.0M 17.4% | $446.0M 16.4% | $378.6M 16.2% | $419.0M 18.5% |
| Interest Expense | $93.8M 2.9% | $93.4M 3.0% | $121.1M 3.7% | $89.0M 2.2% | $57.2M 1.8% | $78.6M 3.1% | $82.6M 2.8% | $58.7M 2.2% | $26.0M 1.1% | $23.9M 1.1% |
| Other Income (Expense), net | -$5.1M -0.2% | $458K 0.0% | -$4.3M -0.1% | -$28.9M -0.7% | $1.6M 0.0% | -$3.1M -0.1% | $2.3M 0.1% | -$1.8M -0.1% | -$829K -0.0% | -$1.0M -0.0% |
| Pretax Income | $482.3M 15.1% | $566.1M 18.0% | $536.1M 16.5% | $564.4M 14.0% | $619.5M 19.1% | $268.1M 10.7% | $462.6M 15.6% | $423.5M 15.6% | $383.5M 16.4% | $421.3M 18.6% |
| Income Tax Expense | $115.0M 3.6% | $145.1M 4.6% | $123.1M 3.8% | $127.8M 3.2% | $131.0M 4.0% | $60.8M 2.4% | $110.4M 3.7% | $106.4M 3.9% | $85.4M 3.7% | $137.1M 6.0% |
| Net Income | $367.3M 11.5% | $428.4M 13.6% | $400.9M 12.4% | $436.6M 10.8% | $488.5M 15.0% | $207.3M 8.2% | $352.2M 11.9% | $317.2M 11.6% | $298.1M 12.8% | $284.2M 12.5% |
| Per Share | ||||||||||
| EPS (Basic) | $-5.38 | $7.97 | $7.48 | $8.07 | $8.85 | $3.76 | $6.33 | $5.71 | $5.26 | $4.98 |
| EPS (Diluted) | $-5.32 | $7.90 | $7.41 | $7.95 | $8.62 | $3.76 | $6.33 | $5.70 | $5.26 | $4.98 |
| Weighted Avg Shares (Basic) | 51.7M | 53.7M | 53.6M | 54.1M | 55.2M | 55.1M | 55.6M | 55.6M | 56.7M | 57.0M |
| Weighted Avg Shares (Diluted) | 52.2M | 54.2M | 54.1M | 54.9M | 56.7M | 55.1M | 55.7M | 55.6M | 56.7M | 57.1M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $724M buybacks = $724M returned on $559M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: -6%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $222M covers the $44M due within a year 5.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2026-01-03 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~4.3% on $2.2B of debt.
Cash of $222M fully covers short-term debt of $44M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 63.1 | 62.7 | 64.9 | 63.2 | 64.1 | 60.4 | 60.3 | 60.9 |
| Gross Profit | 36.9 | 37.3 | 35.1 | 36.8 | 35.9 | 39.6 | 39.7 | 39.1 |
| R&D | 1.3 | 1.4 | 1.4 | 1.3 | 1.2 | 1.5 | 1.6 | 1.8 |
| SG&A | 19.8 | 20.1 | 21.2 | 20.5 | 19.8 | 19.3 | 18.7 | 20.7 |
| Operating Income | 16.4 | 17.4 | 12.9 | 19.4 | 15.9 | 20.1 | 20.4 | 18.0 |
| Income Tax | 3.9 | 3.7 | 2.4 | 4.0 | 3.2 | 3.8 | 4.6 | 3.6 |
| Net Income | 11.6 | 11.9 | 8.2 | 15.0 | 10.8 | 12.4 | 13.6 | 11.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on MIDD: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 651 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LTM | $28.75T | — | — | — | — | — | — | — | — | — | 160 |
| CAT | $364.2B | 41.6× | 29.1× | 5.4× | 4.3% | 33.8% | 13.1% | 41.7% | 15.4% | 2.7× | 3,616 |
| GE | $328.2B | 38.4× | — | 7.2× | 18.5% | — | 19.0% | 46.6% | 22.2% | — | 3,077 |
| RTX | $264.2B | 39.7× | 18.8× | 3.0× | 9.7% | — | 7.6% | 10.3% | 10.3% | 0.0× | 3,277 |
| BA | $204.4B | 81.4× | 41.0× | 2.3× | 34.5% | 4.8% | 2.5% | 41.0% | 3.3% | 10.0× | 2,435 |
| DE | $181.0B | 36.2× | — | 4.0× | -11.7% | — | 11.0% | 19.4% | 12.6% | — | 2,491 |
| ABBNY | $174.3B | 47.1× | 31.1× | 5.4× | 9.5% | 34.8% | 11.9% | 28.5% | 20.4% | 0.9× | 48 |
| UNP | $166.7B | 23.4× | 16.0× | 6.8× | 1.1% | — | 29.1% | 38.7% | 14.2% | 2.6× | 2,648 |
| ETN | $154.3B | 38.1× | — | 5.6× | 10.3% | 37.6% | 14.9% | 21.0% | 13.9% | — | 2,398 |
| HON | $131.9B | 28.2× | 16.2× | 3.5× | 7.8% | 36.9% | 12.6% | 34.0% | 9.8% | 3.6× | 2,694 |
| LMT | $123.0B | 25.0× | 16.1× | 1.6× | 5.6% | 10.2% | 6.7% | 74.6% | 17.7% | 2.5× | 2,807 |
| PH | $117.9B | 33.9× | 26.6× | 5.9× | -0.4% | 36.9% | 17.8% | 25.8% | 16.7% | 1.6× | 1,845 |
| ADP | $108.7B | 25.0× | — | 5.0× | 6.7% | 46.4% | 20.1% | 73.2% | 40.1% | — | 2,179 |
| GD | $97.3B | 23.3× | 17.1× | 1.9× | 10.1% | — | 8.0% | 16.4% | 12.5% | 1.3× | 2,123 |
| TT | $94.0B | 32.5× | 23.2× | 4.4× | 7.5% | — | 13.7% | 34.0% | 22.1% | 1.1× | 1,658 |
| PWR | $92.6B | 91.1× | 46.0× | 3.3× | 20.3% | 15.0% | 3.6% | 11.5% | 10.6% | 0.4× | 1,659 |
| VRT | $91.6B | 70.2× | 43.4× | 8.9× | 27.7% | 36.3% | 13.0% | 33.8% | 19.4% | 1.4× | 1,748 |
| JCI | $91.6B | 27.9× | — | 3.9× | 2.8% | 36.4% | 13.9% | 25.5% | 14.4% | — | 1,487 |
| HWM | $91.5B | 61.4× | 40.3× | 11.1× | 11.1% | — | 18.3% | 28.2% | 17.9% | 1.3× | 1,399 |
| CSX | $89.1B | 31.1× | 14.4× | 6.3× | -3.1% | — | 20.5% | 22.0% | 22.0% | — | 1,791 |
| MMM | $86.2B | 27.1× | 16.6× | 3.5× | 1.5% | 39.9% | 13.0% | 69.1% | 18.8% | 2.1× | 2,051 |
| WM | $86.2B | 31.9× | 12.1× | 3.4× | 14.2% | 40.4% | 10.7% | 27.1% | 25.3% | 0.1× | 2,262 |
| UPS | $83.9B | 15.1× | 9.4× | 0.9× | -2.6% | — | 6.3% | 34.3% | 13.8% | 2.2× | 2,025 |
| EMR | $82.1B | 36.1× | — | 4.6× | 3.0% | 52.8% | 12.7% | 11.3% | 6.9% | — | 2,112 |
| CTAS | $80.4B | 45.3× | 28.9× | 7.8× | 7.7% | 50.0% | 17.5% | 38.7% | 25.5% | 0.8× | 1,366 |
| MIDD | $5.6B | — | 11.1× | 1.8× | 1.6% | 39.1% | -8.7% | -10.0% | -5.6% | 3.2× | 392 |
Peers = companies sharing MIDD's sector (Industrials) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.